Pulmonary Embolism in Covid-19 patients: A French Multicentre Cohort Study

Fauvel, Charles; Weizman, Orianne; Trimaille, Antonin; Mika, Delphine; Pace, Nathalie; Douair, Amine; Barbin, Eva; Fraix, Antoine; Bouchot, Océane; Benmansour, O.; Godeau, Guillaume; Mecheri, Yasmine; Bourdon, R. Le; Yvorel, Cédric; Duceau, Baptiste; Sutter, Willy; Waldmann, Victor; Bonnet, Guillaume; Cohen, Ariel; Pezel, Théo

doi:10.1016/j.acvdsp.2020.10.257

Cited by 32 publications

(64 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this relationship became significant at the time of peak NT-proBNP assessment during admission. Pneumonia and pulmonary embolism are both well-known complications of COVID-19 19,20 and clinical entities in which NT-proBNP has proven useful to improve prognostic stratification. 7,8 Both situations may potentially result in right ventricular strain and higher intracavitary pressures in right cardiac chambers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of NT‐proBNP in a large cohort of COVID‐19 patients

Caro‐Codón

Rey

Buño

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

Aims Extensive research regarding the association of troponin and prognosis in coronavirus disease 2019 (COVID‐19) has been performed. However, data regarding natriuretic peptides are scarce. N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) reflects haemodynamic stress and has proven useful for risk stratification in heart failure (HF) and other conditions such as pulmonary embolism and pneumonia. We aimed to adequately characterize NT‐proBNP concentrations using a large cohort of patients with COVID‐19, and to investigate its association with prognosis. Methods and results Consecutive patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and available NT‐proBNP determinations, from March 1st to April 20th, 2020 who completed at least 1‐month follow‐up or died, were studied. Of 3080 screened patients, a total of 396 (mean age 71.8 ± 14.6 years, 61.1% male) fulfilled all the selection criteria and were finally included, with a median follow‐up of 53 (18–62) days. Of those, 192 (48.5%) presented NT‐proBNP levels above the recommended cut‐off for the identification of HF. However, only 47 fulfilled the clinical criteria for the diagnosis of HF. Patients with higher NT‐proBNP during admission experienced more frequent bleeding, arrhythmias and HF decompensations. NT‐proBNP was associated with mortality both in the whole study population and after excluding patients with HF. A multivariable Cox model confirmed that NT‐proBNP was independently associated with mortality after adjusting for all relevant confounders (hazard ratio 1.28, 95% confidence interval 1.13–1.44, per logarithmic unit). Conclusion NT‐proBNP is frequently elevated in COVID‐19. It is strongly and independently associated with mortality after adjusting for relevant confounders, including chronic HF and acute HF. Therefore, its use may improve early prognostic stratification in this condition.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Myocardial injury is a common complication in patients with coronavirus disease 2019 (COVID- 19) and has been associated with poor outcomes. However, most researchers and definitions have focused on cardiac troponins and cardiac magnetic resonance imaging.…”

Section: Introductionmentioning

confidence: 99%

Characterization of NT‐proBNP in a large cohort of COVID‐19 patients

Caro‐Codón

Rey

Buño

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…An increase of 1.5 years in the mean age of OHCA and death cases during the COVID-19 epidemic compared to that of the previous year was another finding of this study. In another study, 521 of OHCA and death cases during the pandemic (March 16 to April 26, 2020) were compared to the total average number of 3,052 cases during similar weeks in the non-pandemic period (weeks [12][13][14][15][16][17][2012][2013][2014][2015][2016][2017][2018][2019]. It showed that the maximum number of weekly incidences of OHCA and death cases was increased from 13.42 to 26.64 per million inhabitants, although the demographic information of patients like age (mean age: 69.7 versus 68.5 years old) was not significantly different in the pandemic versus the non-pandemic period.…”

Section: Discussionmentioning

confidence: 99%

“…11 Also, the risk of thromboembolic events and acute coronary syndrome is higher in patients with COVID-19, which can increase the incidence of OHCA. 12 Altogether, checking the accuracy of the above-mentioned matters in different societies requires research and investigation. Therefore, the present study aimed to investigate and compare characteristics of Tehran EMS (Iran) missions in OHCA and death cases in the periods of before and after the COVID-19 pandemic.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of Emergency Medical Service Missions in Out-of-Hospital Cardiac Arrest and Death Cases in the Periods of Before and After the COVID-19 Pandemic

Hasani-Sharamin

Saberian

Sadeghi

et al. 2021

Prehosp. Disaster med.

View full text Add to dashboard Cite

Background: Some studies in countries affected by the coronavirus disease of 2019 (COVID-19) pandemic have shown that the missions of Emergency Medical Service (EMS) have changed during the COVID-19 pandemic, and the rate of death and out-of-hospital cardiac arrest (OHCA) has been increased due to the direct and indirect effects of COVID-19. Objective: The aim of this study was to determine the effect of the COVID-19 pandemic on the process of EMS missions, death, and OHCA. Methods: This cross-sectional study was performed in Tehran, Iran. All conducted missions in the first six months of the three consecutive solar years of March 21 until September 22 of 2018-2020, which were registered in the registry bank of the Tehran EMS center, were assessed and compared. Based on the opinion of experts, the technician’s on-scene diagnoses were categorized into 14 groups, and then death and OHCA cases were compared. Results: In this study, the data of 1,050,376 missions performed in three study periods were analyzed. In general, the number of missions in 2020 was 17.83% fewer than that of 2019 (P < .001); however, the number of missions in 2019 was 30.33% more than that of 2018. On the other hand, the missions of respiratory problems, cardiopulmonary arrest, infectious diseases, and poisoning were increased in 2020 compared to that of 2019. The raw number of OHCA and death cases respectively in 2018, 2019, and 2020 were 25.0, 22.7, and 28.6 cases per 1,000 missions. Of all patients who died in 2020, 4.9% were probable/confirmed COVID-19 cases. The history of heart disease, hypertension, diabetes, and respiratory disease in patients in 2020 was more frequent than that of the other two years. Conclusion: This study showed that the number of missions in the Tehran EMS in 2020 were decreased compared to that of 2019, however the number of missions in 2019 was more than that of 2018. Respiratory problems, infectious diseases, poisoning, death, and OHCA were increased compared to the previous two years and cardiovascular complaints, neurological problems, and motor vehicle collisions (MVCs) in 2020 were fewer than that of the other two years

show abstract

“…Dos estudos incluídos, dois (07%) abordaram os fatores de risco para eventos tromboembólicos, nos casos de COVID-19. Os principais fatores de risco foram maior nível sérico de Interleucina-6, taquipneia e diminuição da Saturação Periférica de Oxigênio (SpO2) e outros fatores, relacionados à embolia pulmonar: acidente vascular cerebral prévio, fibrilação atrial, dor torácica ou dispneia (Fauvel, et al, 2020;Garcia-Ortega, et al, 2020).…”

Section: Discussão Gerenciamento Clínico Do Tromboembolismo Venoso E Pulmonarunclassified

Gerenciamento clínico de eventos tromboembólicos provenientes de complicações da COVID-19: revisão integrativa

Bispo

Machado

Paula

et al. 2021

RSD

View full text Add to dashboard Cite

Objetivo: identificar de que forma ocorre o gerenciamento clínico de pacientes infectados por COVID-19 que apresentam tromboembolismo pulmonar e/ou tromboembolismo venoso. Método: Trata-se de uma revisão integrativa, realizada através da busca de artigos nas bases de dados BVS, LILACS, MEDLINE, CINAHL E SCOPUS, com delimitação temporal de novembro de 2019 a março de 2021. Resultados: Foram incluídos 24 artigos. O diagnóstico ocorre através do D-dímero e fibrinogênio. Para a terapia medicamentosa, administra-se a Heparina de baixo peso molecular (HBPM), sendo 30 mg/12h em 12h para a anticogulação profilática, doses escalonadas de HBPM com enoxaparina, 0,5 mg/kg duas vezes por dia para a anticoagulação terapêutica e rivoraxabana 10mg/dia para a anticoagulação pós alta. Conclusão: O gerenciamento clínico de TEP e TEV ocorre através do aumento do D-dímero ou do fibrinogênio, com o TEP confirmado através da angiografia pulmonar. Para a anticoagulação, utiliza-se a HBPM, maiormente.

show abstract

Pulmonary Embolism in Covid-19 patients: A French Multicentre Cohort Study

Cited by 32 publications

References 0 publications

Characterization of NT‐proBNP in a large cohort of COVID‐19 patients

Characterization of NT‐proBNP in a large cohort of COVID‐19 patients

Characteristics of Emergency Medical Service Missions in Out-of-Hospital Cardiac Arrest and Death Cases in the Periods of Before and After the COVID-19 Pandemic

Gerenciamento clínico de eventos tromboembólicos provenientes de complicações da COVID-19: revisão integrativa

Contact Info

Product

Resources

About